Transforming Growth Factor Beta-1 in Human Colorectal Cancer Patients
Özgür Kemik 1 * , Ahu Sarbay Kemik 2, Sevim Purisa 2, İsmail Hasırcı 1, Ahmet Cumhur Dülger 1, Mine Adaş 3, Sefa Tüzün 4
More Detail
1 Yuzuncu Yıl University Medical Faculty, Van, Turkey
2 İstanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey
3 Okmeydanı Training Hospital, Department of Endocrinology, Istanbul, Turkey
4 Haseki Training Hospital, II. General Surgery, Istanbul, Turkey
* Corresponding Author

Abstract

Aim: Colorectal cancer patients are treated with surgery and sometimes radiotherapy and chemotherapy. Transforming growth factor beta-1 (TGF-β1) acts both as an inhibitor of tumor growth and as a promoter of tumor progression. The aim of this study was to determine the levels of TGF-β1 in plasma in colorectal cancer patients and relate these to the effect of clinicopathological variables. Method: One hundred patients scheduled for colorectal cancer surgery were included. Blood samples were taken during surgery and later assayed with enzyme linked immunsorbent assay for total TGF-β1 and active TGF-β1. Result: Total and active TGF-β1 was higher in tumor samples compared to controls (p<0.001).Total TGF-β1 was higher in patients with metastases compared to patients without. Active TGF-β1 levels were not found statistically different in patients with metastases.. Conclusion: Higher levels of total TGF-β1 in plasma at surgery may be indicate of distant metastases, Measurement of total TGF-β1 in colorectal cancer patients may be of clinical use in the future.

License

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article Type: Original Article

https://doi.org/10.29333/ejgm/82697

Eur J Gen Med, 2011 - Volume 8 Issue 1, pp. 53-56

Publication date: 11 Jan 2011

Article Views: 533

Article Downloads: 360

Open Access References How to cite this article